SKU(재고 관리 코드):PAC688Ra01
Polyclonal Antibody to Osteoglycin (OGN)
Polyclonal Antibody to Osteoglycin (OGN)
Western blotting: 0.2-2µg/mL;1:250-2500
Immunohistochemistry: 5-20µg/mL;1:25-100
Immunocytochemistry: 5-20µg/mL;1:25-100
Optimal working dilutions must be determined by end user.
Product No.
PAC688Ra01
Organism Species
Rattus norvegicus (Rat).
Source
Polyclonal antibody preparation
Host
Rabbit
Potency
n/a
Ig Type
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
RPC688Ra01-Recombinant Osteoglycin (OGN)
Buffer Formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
Traits
Liquid
Concentration
500µg/mL
Organism Species More
Homo sapiens (Human), Mus musculus (Mouse)
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against OGN. It has been selected for its ability to recognize OGN in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.2-2µg/mL;1:250-2500
Immunohistochemistry: 5-20µg/mL;1:25-100
Immunocytochemistry: 5-20µg/mL;1:25-100
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
Magazine |
Citations |
Bone. |
Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus. pubmed:27836731 |
Tohoku journal of experimental medicine |
Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. pubmed:28824047 |
Molecular Metabolism |
Osteoglycin, a novel coordinator of bone and glucose homeostasis Pubmed:29799418 |
Journal of Experimental & Clinical Cancer Research |
Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway Pubmed:29499765 |
Journal of Human Hypertension |
Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients Pubmed:29867136 |
Cell Reports |
Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue Pubmed: 30332637 |
J Clin Endocrinol Metab |
Osteoglycin across the adult lifespan 34850904 |
Catalog No. |
Related products for research use of Rattus norvegicus (Rat) Organism species |
Applications (RESEARCH USE ONLY!) |
RPC688Ra01 |
Positive Control; Immunogen; SDS-PAGE; WB. |
|
PAC688Ra01 |
WB; IHC; ICC; IP. |
|
LAC688Ra71 |
WB; IHC; ICC. |